| 1 |
35598359 | Olaparib tolerability and common adverse-event management in patients with metastatic castration-resistant prostate cancer: Further analyses from the PROfound study. | 2022 May 18 |
1 |
| 2 |
32778095 | Precision medicine phase II study evaluating the efficacy of a double immunotherapy by durvalumab and tremelimumab combined with olaparib in patients with solid cancers and carriers of homologous recombination repair genes mutation in response or stable after olaparib treatment. | 2020 Aug 10 |
1 |
| 3 |
30703739 | A phase I/II trial of olaparib tablet in combination with eribulin in Japanese patients with advanced or metastatic triple-negative breast cancer previously treated with anthracyclines and taxanes. | 2019 Mar |
1 |
| 4 |
29152107 | Neoadjuvant olaparib targets hypoxia to improve radioresponse in a homologous recombination-proficient breast cancer model. | 2017 Oct 20 |
2 |
| 5 |
27323902 | A phase I followed by a randomized phase II trial of two cycles carboplatin-olaparib followed by olaparib monotherapy versus capecitabine in BRCA1- or BRCA2-mutated HER2-negative advanced breast cancer as first line treatment (REVIVAL): study protocol for a randomized controlled trial. | 2016 Jun 21 |
1 |
| 6 |
27422301 | Safety and tolerability of the olaparib tablet formulation in Japanese patients with advanced solid tumours. | 2016 Sep |
1 |
| 7 |
26048134 | Effect of Food on the Pharmacokinetics of Olaparib after Oral Dosing of the Capsule Formulation in Patients with Advanced Solid Tumors. | 2015 Jun |
1 |
| 8 |
23810467 | A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer. | 2013 Sep |
1 |